The global hysteroscopy procedures market size is expected to reach USD 7.4 billion by 2030, expanding at a CAGR of 7.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Surge in prevalence of gynecological disorders, technological advancements, increasing adoption of minimally invasive surgeries, and favorable reimbursement policies are the key driving factors for the market. In addition, the impact of the COVID-19 pandemic has been significant on the market.
The pandemic has affected companies’ ability to develop and commercialize new & advanced products. Almost all companies are affected by reduced procedure volumes due to the pandemic, as all hospital resources are being diverted to fight the disease. Furthermore, the restrictions and functioning of a limited number of government offices are expected to delay clinical trials of products, which is expected to result in delayed product launches by companies.
The increasing prevalence of uterine fibroids is a key factor driving the market. For instance, as per the research article published in Dove Press Ltd., the prevalence of uterine fibroid disease ranges from 5.4% to 23.6%, depending upon the age group. Moreover, uterine fibroids can cause serious problems in 25% of women. Hysteroscopy is used to diagnose abnormalities, such as excessive bleeding, severe stomach cramps, recurrent miscarriages, or difficulties in conceiving. Thus, the presence of such a large patient pool leads to increased demand for hysteroscopy procedures.
Request a free sample copy or view report summary: Hysteroscopy Procedures Market Report
The hospitals end-use segment held the largest revenue share of over 52.4% in 2023. The segment growth is credited to the high number of cases of gynecological disorders
Asia Pacific is expected to witness the fastest CAGR over the forecast period due to the presence of a large patient pool coupled with the rising aging population in the APAC region
Integrating hysteroscopy into office practice will provide a lucrative opportunity for key market players. Several players have launched office hysteroscopy and associated devices
For instance, Aveta System (office hysteroscopy), recently launched by Meditrina Inc. in March 2020, is an all-in-one tissue removal solution for intrauterine pathology, which offers wide-angle HD hysteroscopy
Furthermore, in-office hysteroscopy is beneficial over traditional hysteroscopy procedures as it is efficient & clinically beneficial and offers a patient-centric approach
It is also a simple and quick tool for retrieving intrauterine devices. Thus, physicians will consider investing in equipment and adopting an in-office approach for hysteroscopy
Grand View Research has segmented the global hysteroscopy procedures market on the basis of procedure, end-use and region:
Hysteroscopy Procedures CPT Code Outlook (Revenue, USD Million, 2018 - 2030)
58555
58558
58562
58340
58563
58565
58353
58561,74740 and more (Others)
Hysteroscopy Procedures End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Clinics
Ambulatory Surgery Centers
Hysteroscopy Procedures Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Hysteroscopy Procedures Market
Medtronic
Stryker Corp.
Hologic, Inc.
KARL STORZ SE & Co. KG
Medical Devices Business Services, Inc. (Ethicon, Inc.)
Olympus Corp.
Delmont Imaging
B. Braun Melsungen AG
Richard Wolf GmbH
CooperCompanies
Maxer Endoscopy GmbH
Boston Scientific Corp.
MedGyn Products, Inc.
Lina Medical APS
Luminelle
Meditrina, Inc. (Aveta)
"The quality of research they have done for us has been excellent..."